文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

依曲韦林换用多拉韦林在携带NNRTI耐药突变HIV感染者中的初步研究

Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

DorSwitch前瞻性试点研究纳入13例病毒学抑制且既往有NNRTI相关耐药突变的成人HIV感染者,将依曲韦林换为多拉韦林并维持其余方案。多数患者多拉韦林耐药罚分不高于依曲韦林,血脂下降,安全性良好。

要点

  • 病毒学抑制且既往NNRTI耐药者换用多拉韦林48周无病毒学失败
  • 11/13例多拉韦林耐药罚分低于或等于依曲韦林
  • 合用达芦那韦/考比司他时多拉韦林谷浓度符合预期暴露

核心结论

  • 在高度选择的试点队列中,依曲韦林换用多拉韦林并维持其余抑制性方案,48周维持病毒学抑制且多数患者预测NNRTI耐药谱更优。

研究设计与样本

  • DorSwitch为前瞻性试点研究,纳入13例病毒学持续抑制且既往有NNRTI相关耐药突变的成人HIV感染者。
  • 将依曲韦林替换为多拉韦林并维持其余抗逆转录病毒骨干方案,随访48周。

主要发现

  • 第24周和第48周所有可评估者HIV-1 RNA<50 copies/mL,无病毒学失败。
  • 每例NNRTI耐药突变中位数为2个(IQR 1-3)。
  • 11/13例多拉韦林Stanford HIVdb罚分低于或等于依曲韦林。
  • 7例合用达芦那韦/考比司他者的多拉韦林谷浓度符合预期暴露浓度。

关键数值与推荐

  • 两例多拉韦林罚分较高由外周血单核细胞HIV-1 DNA中Y318F和G190E突变驱动,均维持病毒学抑制至第48周。
  • 随访期间总胆固醇和LDL胆固醇显著下降,体重呈轻度非显著下降。
  • 未观察到多拉韦林相关严重不良事件。

临床怎么用

  • 对病毒学抑制且既往NNRTI失败、携带NNRTI耐药突变者,多拉韦林可作为谨慎选择后的换药选项,尤其与达芦那韦/考比司他联用时。
  • 换药前应结合HIVdb耐药罚分评估多拉韦林与依曲韦林的耐药谱差异。

局限性

  • 样本量小(13例)且为高度选择的试点队列,结论需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study is to evaluate the efficacy, resistance profile, pharmacokinetics (PK) and safety of switching from etravirine to doravirine in virologically suppressed, treatment-experienced individuals with prior non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated resistance mutations (NNRTI-RAMs). METHODS: DorSwitch is a prospective pilot study including 13 adults with sustained virological suppression and documented historical NNRTI-RAMs. Etravirine was replaced by doravirine while maintaining the remaining antiretroviral backbone. Drug-specific resistance penalty scores were generated using the Stanford HIV Drug Resistance Database (HIVdb) algorithm. PK analyses were performed in participants receiving darunavir/cobicistat plus doravirine. Virological, immunological, metabolic and safety outcomes were assessed over 48 weeks. RESULTS: Twelve participants completed 48 weeks of follow-up; one discontinued at Week 4 for personal reasons while virologically suppressed. All participants evaluable at Weeks 24 and 48 maintained HIV-1 RNA < 50 copies/mL, and no virological failures occurred. The median number of NNRTI-RAMs per individual was 2 (IQR 1-3). Doravirine showed lower or equal Stanford HIVdb penalty score (HIVdb-PS) than etravirine in 11/13 participants. In two cases, higher doravirine PS were driven by Y318F and G190E mutations detected in peripheral blood mononuclear cell HIV-1 DNA; both individuals remained virologically suppressed through Week 48. In seven participants receiving darunavir/cobicistat plus doravirine, trough concentrations (Cmin) were consistent with expected exposure concentrations. Total cholesterol and LDL cholesterol decreased significantly over follow-up, while body weight showed a modest, non-significant reduction. No doravirine-related serious adverse events were observed. CONCLUSIONS: In this small, highly selected pilot cohort, switching from etravirine to doravirine as part of an otherwise suppressive regimen was associated with maintenance of virological suppression through Week 48 and a more favourable predicted NNRTI resistance profile in most participants. The favourable resistance profile, safety, metabolic effects and PK findings consistent with expected exposure-particularly in combination with darunavir/cobicistat- support further evaluation of doravirine as a switch option in carefully selected individuals with prior NNRTI failure.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Sempere A, de la Mora L, Inciarte A, et al. Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study. J Antimicrob Chemother. 2026. PMID: 42695345. doi:10.1093/jac/dkag297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。